Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

18th Congress of EHA

13 - 14 Jun 2013
Stockholmsmassan, Stockholm, Sweden
Advances in Multiple Myeloma from EHA 2013
Prof Gareth Morgan - The Royal Marsden Hospital, London
Advances in Multiple Myeloma from EHA 2013 ( Prof Gareth Morgan - The Royal Marsden Hospital, London )
2 Jul 2013
An update from Myeloma UK
Eric Low - CEO, Myeloma UK
An update from Myeloma UK ( Eric Low - CEO, Myeloma UK )
2 Jul 2013
Newly diagnosed multiple myeloma patients
Dr Alessandra Larocca - University of Torino, Italy
Newly diagnosed multiple myeloma patients ( Dr Alessandra Larocca - University of Torino, Italy )
2 Jul 2013
Anaemia update from EHA 2013
Prof Valeria Santini – University of Florence, Italy
Anaemia update from EHA 2013 ( Prof Valeria Santini – University of Florence, Italy )
28 Jun 2013
Chronic lymphocytic leukaemia update from EHA 2013
Prof John Gribben - Barts & The London Trust Cancer Centre, UK and Dr Jacqueline...
Chronic lymphocytic leukaemia update from EHA 2013 ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK and Dr Jacqueline Barrientos - North Shore-LIJ School of Medicine, USA )
28 Jun 2013
Advances in Multiple Myeloma from EHA 2013
Prof Michele Cavo - University of Bologna, Italy and Prof Philippe Moreau - Cent...
Advances in Multiple Myeloma from EHA 2013 ( Prof Michele Cavo - University of Bologna, Italy and Prof Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France )
28 Jun 2013
Acute myeloid leukaemia (AML) at EHA 2013
Prof Gert Ossenkoppele - VU University Medical Center, The Netherlands
Acute myeloid leukaemia (AML) at EHA 2013 ( Prof Gert Ossenkoppele - VU University Medical Center, The Netherlands )
25 Jun 2013
The future management of mantle cell lymphoma
Dr Simon Rule - Derriford Hospital, Plymouth, UK and Dr Martin Dreyling - Ludwig...
The future management of mantle cell lymphoma ( Dr Simon Rule - Derriford Hospital, Plymouth, UK and Dr Martin Dreyling - Ludwig Maximilians-University, Munich, Germany )
25 Jun 2013
Relapsed or progressive multiple myeloma
Dr Ruben Niesvizky - Weill Cornell Medical College, New York, USA
Relapsed or progressive multiple myeloma ( Dr Ruben Niesvizky - Weill Cornell Medical College, New York, USA )
20 Jun 2013
Pomalidomide prolongs survival in refractory multiple myeloma patients
Prof Jesus San Miguel - University Hospital of Salamanca, Salamanca, Spain
Pomalidomide prolongs survival in refractory multiple myeloma patients ( Prof Jesus San Miguel - University Hospital of Salamanca, Salamanca, Spain )
19 Jun 2013
Carfilzomib plus melphalanprednisone in elderly patients with newly diagnosed mu...
Prof Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France
Carfilzomib plus melphalanprednisone in elderly patients with newly diagnosed multiple myeloma ( Prof Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France )
19 Jun 2013
Age and ageing in blood disorders
Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands
Age and ageing in blood disorders ( Prof Pieter Sonneveld - University Hospital Rotterdam, Netherlands )
19 Jun 2013
Rituximab for b-cell lymphoma and EHA overview
Prof Ulrich Jäger - EHA President and Vienna Medical University, Austria
Rituximab for b-cell lymphoma and EHA overview ( Prof Ulrich Jäger - EHA President and Vienna Medical University, Austria )
19 Jun 2013
Highlights from EHA 2013
Prof Anton Hagenbeek - Universitair Medisch Centrum Utrecht, Heidelberglaan, Net...
Highlights from EHA 2013 ( Prof Anton Hagenbeek - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )
19 Jun 2013
Patient advocacy track 'personalised medicine'
Prof Anton Hagenbeek - Universitair Medisch Centrum Utrecht, Heidelberglaan, Net...
Patient advocacy track 'personalised medicine' ( Prof Anton Hagenbeek - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )
19 Jun 2013
Second line treatment of multiple myeloma with melphalan prednisone and lenalido...
Prof Meletios Dimopoulos - Univeristy of Athens, Greece
Second line treatment of multiple myeloma with melphalan prednisone and lenalidomide ( Prof Meletios Dimopoulos - Univeristy of Athens, Greece )
19 Jun 2013
Challenges facing haematologists treating acute myeloid leukaemia
Dr Dalia Mahmoud - Celgene Corporation, Summit, USA
Challenges facing haematologists treating acute myeloid leukaemia ( Dr Dalia Mahmoud - Celgene Corporation, Summit, USA )
19 Jun 2013
JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neop...
Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA
JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms ( Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA )
19 Jun 2013
Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma
Dr Annamaria Brioli - The Institute of Cancer Research, Sutton, UK
Cyclophosphamide lenalidomide and dexamethasone in newly diagnosed myeloma ( Dr Annamaria Brioli - The Institute of Cancer Research, Sutton, UK )
19 Jun 2013
Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chr...
Dr Valentin Goede - University Hospital of Cologne, Germany
Addition of obinutuzumab or rituximab to chlorambucil improves outcomes for chronic lymphocytic leukaemia ( Dr Valentin Goede - University Hospital of Cologne, Germany )
19 Jun 2013
Long-term outcomes with ruxolitinib and best available therapy for the treatment...
Prof Alessandro Vannucchi - University of Florence, Florence, Italy
Long-term outcomes with ruxolitinib and best available therapy for the treatment of myelofibrosis ( Prof Alessandro Vannucchi - University of Florence, Florence, Italy )
19 Jun 2013
Strategies to maintain remission in high risk CD19 lymphoid malignancies
Dr Partow Kebriaei - MD Anderson Cancer Center, Houston, USA
Strategies to maintain remission in high risk CD19 lymphoid malignancies ( Dr Partow Kebriaei - MD Anderson Cancer Center, Houston, USA )
19 Jun 2013
Von Willebrand Factor and ADAMTS13
Dr Evan Sadler - Washington University in St Louis, USA
Von Willebrand Factor and ADAMTS13 ( Dr Evan Sadler - Washington University in St Louis, USA )
19 Jun 2013
Use of autologous stem cell transplant in multiple myeloma
Dr Elena Zamagni - Bologna University School of Medicine, Bologna, Italy
Use of autologous stem cell transplant in multiple myeloma ( Dr Elena Zamagni - Bologna University School of Medicine, Bologna, Italy )
19 Jun 2013
International workshop on chronic lymphocytic leukaemia 2013
Prof Michael Hallek - University Clinic of Cologne, Cologne, Germany
International workshop on chronic lymphocytic leukaemia 2013 ( Prof Michael Hallek - University Clinic of Cologne, Cologne, Germany )
18 Jun 2013
Study shows pomalidomide prolongs survival in refractory myeloma patients
Prof Jesus San Miguel - University Hospital of Salamanca, Salamanca, Spain
Study shows pomalidomide prolongs survival in refractory myeloma patients ( Prof Jesus San Miguel - University Hospital of Salamanca, Salamanca, Spain )
18 Jun 2013
Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma
Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, N...
Use of Daratumumab, a CD38 monoclonal antibody, in advanced multiple myeloma ( Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )
18 Jun 2013
Targeting JAK-STAT pathway in malignant and non-malignant cells in myeloprolifer...
Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA
Targeting JAK-STAT pathway in malignant and non-malignant cells in myeloproliferative neoplasms ( Dr Ross Levine - Memorial Sloan-Kettering Cancer Center, New York, USA )
18 Jun 2013
Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic ...
Dr Valentin Goede - University Hospital of Cologne, Germany
Addition of obinutuzumab or rituximab to chlorambucil for chronic lymphocytic leukaemia ( Dr Valentin Goede - University Hospital of Cologne, Germany )
18 Jun 2013
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma
Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, N...
Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma ( Prof Heinrich Lokhorst - Universitair Medisch Centrum Utrecht, Heidelberglaan, Netherlands )
17 Jun 2013